Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?
Eli Lilly's tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, shows promise in treating sleep apnea, with recent studies indicating significant reductions in sleep apnea events. Lilly seeks FDA approval for this expanded use, potentially boosting sales. The company's strong pipeline, including Alzheimer's drug donanemab, and robust financial performance, driven by high demand for its drugs, position it well for future growth.
Reference News
Eli Lilly's tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, shows promise in treating sleep apnea, with recent studies indicating significant reductions in sleep apnea events. Lilly seeks FDA approval for this expanded use, potentially boosting sales. The company's strong pipeline, including Alzheimer's drug donanemab, and robust financial performance, driven by high demand for its drugs, position it well for future growth.